Enfortumab vedotin + Pembrolizumab

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Muscle Invasive Bladder Urothelial Carcinoma

Conditions

Muscle Invasive Bladder Urothelial Carcinoma

Trial Timeline

Apr 7, 2025 → Nov 1, 2029

NCT ID

NCT06809140

About Enfortumab vedotin + Pembrolizumab

Enfortumab vedotin + Pembrolizumab is a phase 2 stage product being developed by Astellas Pharma for Muscle Invasive Bladder Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06809140. Target conditions include Muscle Invasive Bladder Urothelial Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07475806	Phase 2	Recruiting	Mar 31, 2026	Apr 30, 2031	Muscle-invasive Bladder Cancer
NCT06906822	Phase 2	Recruiting	Jun 10, 2025	Jun 1, 2028	Melanoma
NCT06809140	Phase 2	Recruiting	Apr 7, 2025	Nov 1, 2029	Muscle Invasive Bladder Urothelial Carcinoma
NCT06470282	Phase 1/2	Recruiting	Mar 31, 2025	Jan 31, 2028	Bladder Cancer
NCT05756569	Phase 2	Recruiting	Sep 26, 2023	Dec 16, 2027	Bladder Squamous Cell Carcinoma
NCT05239624	Phase 2	Recruiting	Jun 2, 2022	Jun 1, 2027	Urothelial Carcinoma
NCT04225117	Phase 2	Active	Mar 9, 2020	Sep 30, 2026	Locally Advanced or Metastatic Malignant Solid Tumors

Competing Products

20 competing products in Muscle Invasive Bladder Urothelial Carcinoma

See all competitors

Product	Company	Stage	Hype Score
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	51
Enfortumab Vedotin + Pembrolizumab	Astellas Pharma	Phase 2	52
Pembrolizumab + Enfortumab Vedotin	Astellas Pharma	Phase 3	77
Eperisone	Eisai	Phase 3	77
LY2495655 + Placebo	Eli Lilly	Phase 2	52
HRS-9190	Jiangsu Hengrui Medicine	Phase 1	33
HRS-9190 for Injection	Jiangsu Hengrui Medicine	Phase 1	33
Botulinum Toxin Type A	AbbVie	Phase 3	77
BOTOX + Placebo	AbbVie	Phase 3	77
BOTOX + Placebo	AbbVie	Phase 3	77
BOTOX + Placebo for BOTOX	AbbVie	Phase 3	77
BOTOX + Placebo	AbbVie	Phase 3	77
Durvalumab + Tremelimumab + Enfortumab Vedotin	AstraZeneca	Phase 3	77
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)	AstraZeneca	Phase 3	77
Durvalumab + Oleclumab	AstraZeneca	Phase 1	33
AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + Selumetinib	AstraZeneca	Phase 1	33
Durvalumab + Cisplatin + Gemcitabine	AstraZeneca	Phase 3	77
Durvalumab + BCG	AstraZeneca	Phase 3	77
Durvalumab + Monalizumab	AstraZeneca	Phase 2	52
Durvalumab (Imfinzi) + Tremelimumab	AstraZeneca	Phase 2	52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved